Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Yuyu Pharma, Inc. (000220) Stock Price & Analysis

000220 Stock Chart & Stats

₩3,650.00₩0.00(0.00%)
At close: 3:30 PM GMT+9
KRW 3,500KRW 3,7503 Aug18 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
KRW 3,600.00 - KRW 3,710.00
52-Week Range
KRW 3,320.00 - KRW 5,100.00
Previous Close
KRW 3,650.00
Volume
N/A
Average Volume (3M)
44.05K
Market Cap
KRW 52.79B
Enterprise Value
KRW 74.33B
Total Cash (Recent Filing)
KRW 27.86B
Total Debt (Recent Filing)
KRW 28.06B
Price to Earnings (P/E)
4.9
Beta
0.13
Next Earnings
Nov 18, 2026 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Dec 29, 2025
Dividend Yield
3.15%

Bulls Say, Bears Say

Bulls Say

Profitability Recovery

Net income turned solidly positive in 2024–2025 and remained strong in TTM, showing meaningful recovery from losses. If maintained, this improves internal funding capacity and supports reinvestment, financial resilience, and more durable earnings power over the medium term.

Revenue Growth

Accelerating TTM revenue growth indicates stronger demand or commercial momentum than in the prior annual period. Sustained top-line expansion can improve operating leverage, broaden the company’s earnings base, and support continued investment in its pharmaceutical portfolio.

Conservative Balance Sheet

Modest leverage and improving equity provide a stronger financial foundation for a pharmaceutical business. This balance-sheet resilience can reduce financing pressure, preserve flexibility for operations and investment, and help the company withstand periods of earnings volatility.

Bears Say

Inconsistent Operating Profitability

Material variation in operating and EBITDA margins makes the recent earnings recovery less predictable than the headline net income improvement suggests. Uneven cost absorption, product mix, or other period-specific effects could limit the durability of operating profits.

Uneven Cash Conversion

Positive operating cash flow and free cash flow are encouraging, but weak conversion of TTM net income into free cash flow reduces the quality of reported earnings. Cash-flow volatility may constrain internally funded investment and make results more sensitive to working-capital or investment needs.

History Of Earnings Volatility

The shift from losses in 2022–2023 to strong recent profits demonstrates recovery, but it also shows that earnings can change materially across the cycle. A recurrence of weaker operating conditions would create uncertainty around the persistence of current profitability and returns.

000220 FAQ

What was Yuyu Pharma, Inc.’s price range in the past 12 months?
Yuyu Pharma, Inc. lowest stock price was ₩3320.00 and its highest was ₩5100.00 in the past 12 months.
What is Yuyu Pharma, Inc.’s market cap?
Yuyu Pharma, Inc.’s market cap is ₩52.79B.
When is Yuyu Pharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Yuyu Pharma, Inc.’s earnings last quarter?
Yuyu Pharma, Inc. released its earnings results on Aug 13, 2026. The company reported ₩231.833 earnings per share for the quarter.
Is Yuyu Pharma, Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Yuyu Pharma, Inc. pay dividends?
Yuyu Pharma, Inc. pays a ― dividend of ₩115 which represents an annual dividend yield of 3.15%. See more information on Yuyu Pharma, Inc. dividends here
What is Yuyu Pharma, Inc.’s EPS estimate?
Yuyu Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yuyu Pharma, Inc. have?
Yuyu Pharma, Inc. has 15,747,462 shares outstanding.
What happened to Yuyu Pharma, Inc.’s price movement after its last earnings report?
Yuyu Pharma, Inc. reported an EPS of ₩231.833 in its last earnings report. Following the earnings report the stock price went down -1.575%.
Which hedge fund is a major shareholder of Yuyu Pharma, Inc.?
Currently, no hedge funds are holding shares in KR:000220
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology